Erythropoietin: When liability becomes asset in neurovascular repair

Maria B. Grant, Michael E. Boulton, Alexander V. Ljubimov

Research output: Contribution to journalComment/debate

21 Scopus citations

Abstract

Erythropoietin (Epo) leads to the proliferation and differentiation of erythroid precursors, but is also involved in diverse nonhematopoietic biological functions. In this issue of the JCI, Chen, Smith, and colleagues demonstrate that the temporal expression of Epo is critical for determining whether physiological or pathological repair occurs following neurovascular retinal injury in the oxygen-induced retinopathy neonatal mouse model (see the related article beginning on page 526). The pleiotrophic properties of Epo make it a likely novel therapy for treatment of neurovascular damage, but the timing of its use must be carefully considered to prevent untoward effects.

Original languageEnglish (US)
Pages (from-to)467-470
Number of pages4
JournalJournal of Clinical Investigation
Volume118
Issue number2
DOIs
StatePublished - Feb 1 2008

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Erythropoietin: When liability becomes asset in neurovascular repair'. Together they form a unique fingerprint.

  • Cite this